EZH2 and neoplasm: Our findings agree with data from solid tumours and other haematological malignancies in which upregulation of EZH2 has been linked to tumour aggressiveness and poor outcomes.22, 23, 24 Some studies have suggested that EZH2 might be involved in transcriptional activation rather than repression and that this activation might drive tumour progression.